EZH2 is altered in 1.19% of malignant solid tumor patients with EZH2 Loss present in 0.03% of all malignant solid tumor patients [4].

EZH2 Loss is an inclusion criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain EZH2 Loss and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

EZH2 is altered in 5.77% of myelodysplastic syndromes patients with EZH2 Loss present in 0.55% of all myelodysplastic syndromes patients [4].

EZH2 Loss is an inclusion criterion in 4 clinical trials for myelodysplastic syndromes, of which 4 are open and 0 are closed. Of the trials that contain EZH2 Loss and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

EZH2 is altered in 3.38% of acute myeloid leukemia patients with EZH2 Loss present in 0.19% of all acute myeloid leukemia patients [4].

EZH2 Loss is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain EZH2 Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

EZH2 is altered in 8.16% of chronic myelomonocytic leukemia patients [4].

EZH2 Loss is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain EZH2 Loss and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

EZH2 is altered in 11.53% of diffuse large B-cell lymphoma patients with EZH2 Loss present in 0.2% of all diffuse large B-cell lymphoma patients [4].

EZH2 Loss is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EZH2 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

EZH2 is altered in 8.7% of non-hodgkin lymphoma patients with EZH2 Loss present in 0.07% of all non-hodgkin lymphoma patients [4].

EZH2 Loss is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EZH2 Loss and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

EZH2 is altered in 3.48% of melanoma patients with EZH2 Loss present in 0.05% of all melanoma patients [4].

EZH2 Loss is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain EZH2 Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

EZH2 is altered in 19.08% of follicular lymphoma patients [4].

EZH2 Loss is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EZH2 Loss and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

EZH2 is altered in 7.23% of secondary acute myeloid leukemia patients [4].

EZH2 Loss is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain EZH2 Loss and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EZH2 is altered in 6.06% of myelodysplastic/myeloproliferative neoplasm, unclassifiable patients with EZH2 Loss present in 11.11% of all myelodysplastic/myeloproliferative neoplasm, unclassifiable patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

EZH2 is altered in 1.16% of malignant peripheral nerve sheath tumor patients with EZH2 Loss present in 1.2% of all malignant peripheral nerve sheath tumor patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

EZH2 is altered in 7.12% of myelodysplastic/myeloproliferative neoplasm patients with EZH2 Loss present in 0.98% of all myelodysplastic/myeloproliferative neoplasm patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

EZH2 is altered in 0.75% of sarcoma patients with EZH2 Loss present in 0.17% of all sarcoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 7.61% of lymphoma patients with EZH2 Loss present in 0.11% of all lymphoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 10.8% of B-cell non-hodgkin lymphoma patients with EZH2 Loss present in 0.09% of all B-cell non-hodgkin lymphoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

EZH2 is altered in 0.48% of pancreatic carcinoma patients with EZH2 Loss present in 0.04% of all pancreatic carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 0.89% of breast carcinoma patients with EZH2 Loss present in 0.02% of all breast carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 1.21% of colorectal carcinoma patients with EZH2 Loss present in 0.02% of all colorectal carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

EZH2 is altered in 1.58% of anaplastic astrocytoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 1.31% of bladder carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 Loss is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and epithelioid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EZH2 is altered in 1.46% of glioblastoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 1.19% of head and neck carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

EZH2 is altered in 0.41% of multiple myeloma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [5].

EZH2 is altered in 7.83% of myelofibrosis patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [5].

EZH2 is altered in 0.96% of non-small cell lung carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 is altered in 0.93% of ovarian carcinoma patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

EZH2 Loss is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains EZH2 Loss and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

EZH2 Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and rhabdoid tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

EZH2 Loss is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and synovial sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EZH2 is altered in 7.23% of therapy-related acute myeloid leukemia patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

EZH2 is altered in 4.23% of therapy-related myelodysplastic syndrome patients [4].

EZH2 Loss is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains EZH2 Loss and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].